New patent expands TheraCell’s osteobiologic patent portfolio

Northridge, Calif. and Centennial, Colo. — May 2, 2017 — TheraCell, a regenerative medicine company, today announced the issuance of a new patent for its enhanced cancellous demineralized bone (ECS) technology by the United States Patent and Trademark Office. The addition of U.S. Patent Number 9,636,436 entitled Compositions of and Methods for Cancellous Bone Matrix, expands TheraCell’s intellectual property portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry.

Demineralized cancellous sponge products make up a significant portion of the allograft market. The architecture of cancellous bone provides a highly osteoconductive matrix but has minimal osteoinductive properties. TheraCell’s enhanced cancellous technology is a minimally manipulated tissue product that combines the osteoinductivity of demineralized cortical bone powder with the osteoconductivity of demineralized cancellous bone for enhanced performance.

“The ECS technology enhances the performance of cancellous bone products and is a novel approach that has tremendous potential in a range of surgical bone grafting applications,” said Nelson Scarborough, PhD, Chief Scientific Officer, TheraCell, Inc.

“The issuance of this patent along with TheraCell’s other recently issued patents on Demineralized Bone Fiber (DBF) and oxygenation technologies has built a strong portfolio of intellectual property covering our platform of technologies. In addition to their standalone value there is also excellent synergistic potential to create next generation orthobiologic products,” said Bradley Patt, PhD, Chief Executive Officer.

For more information on these products, please visit TheraCell’s website.


About TheraCell, Inc.
TheraCell, Inc. is a regenerative medicine company developing the next generation of advanced technologies for tissue repair for both the human and veterinary markets. TheraCell has four synergistic technology platforms. The first of these is a proprietary process for making demineralized bone fibers (DBF). The second platform is an oxygenation technology. Oxygenation leads to improved tissue regeneration. The third technology platform is a process for infusing demineralized cortical bone powder into cancellous bone. The fourth technology platform is a point of care stem cell isolation and purification system. Founded in 2008, the firm is headquartered in Los Angeles and maintains offices, laboratories and production facilities in Littleton, MA. ECS and DBF are trademarks of TheraCell, Inc.